MorphoSys AG / MorphoSys Licenses HuCAL PLATINUM® Antibody Library to Shionogi in Research Partnership processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. 

MorphoSys  AG (FSE:  MOR; Prime  Standard Segment,  TecDAX) announced today that
Shionogi  & Co., Ltd., Osaka, Japan, has  elected to expand its current research
license  to  cover  the  use  of  MorphoSys's  HuCAL PLATINUM technology in drug
discovery. In April 2009, MorphoSys and Shionogi entered into an agreement under
which,  for pre-agreed terms, Shionogi could  gain access to HuCAL PLATINUM, the
latest  and most powerful MorphoSys antibody  library, for a six-month beta test
period.  During this  test period,  Shionogi was  able to compare HuCAL PLATINUM
with its predecessor HuCAL GOLD(®), and found the new library to be considerably
better.

"We  have had the pleasure of using the MorphoSys HuCAL PLATINUM library for the
last  six months and were extremely  impressed. HuCAL PLATINUM's capabilities go
beyond  any other antibody sourcing library we have used in the past, and we are
very  excited about being  able to continue  to use the  PLATINUM library in the
future,"  commented Dr. Yoshito Numata,  Department Head, Drug Target Discovery,
Discovery Research Laboratory.

"Shionogi has been able to test-drive the latest version of our antibody library
HuCAL  PLATINUM extensively. Thus,  their decision to  upgrade speaks clearly to
the  quality  and  the  success  of  our internal technology development work in
recent  years,"  commented  Dr.  Marlies  Sproll,  Chief  Scientific  Officer of
MorphoSys.

Under  the terms of the agreement, Shionogi will now have the right to use HuCAL
PLATINUM  for  research  purposes  at  one  of  its  sites.  As  a result of the
expansion,  MorphoSys  will  receive  increased  annual user fees from Shionogi.
Further financial details were not disclosed.

MorphoSys  and  Shionogi  signed  a  three-year  license agreement on the use of
MorphoSys's   HuCAL  technology  in  September  2005. Under  the  terms  of  the
agreement,  MorphoSys granted Shionogi access to its HuCAL GOLD antibody library
for  research applications in  Shionogi's drug discovery  programs. The research
alliance  was extended for  three additional years  in September 2008. The HuCAL
PLATINUM  library was  introduced in  September 2008. PLATINUM  contains several
significant improvements over the previous version of the HuCAL library. The new
library  is  based  on  the  genetic  information  of  approximately  45 billion
different fully human antibodies.


About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for  therapeutic,  diagnostic  and  research  applications.  The Company's HuCAL
technology  is one of  the most powerful  methods available for generating fully
human   antibodies.   By   successfully  applying  this  and  other  proprietary
technologies,  MorphoSys  has  become  a  leader  in  the  field  of therapeutic
antibodies,  one  of  the  fastest-growing  drug  classes  in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding  its drug pipeline by adding new partnered programs, and by building a
portfolio  of fully-owned therapeutic antibodies. For its proprietary portfolio,
the  Company is  focused on  the areas  of oncology  and inflammation.  Its most
advanced  program MOR103, a first-in-class, fully human antibody against GM-CSF,
is  currently tested in  a Phase Ib/IIa  trial in rheumatoid arthritis patients.
Via  its business  unit AbD  Serotec, MorphoSys  is expanding  the reach  of its
technologies in the diagnostics and research markets. MorphoSys is headquartered
in  Munich, Germany and listed on the  Frankfurt Stock Exchange under the symbol
"MOR". For further information, visit http://www.morphosys.com/


HuCAL(®),  HuCAL  GOLD(®),  HuCAL  PLATINUM(®),  CysDisplay(® )and RapMAT(®) are
registered trademarks of MorphoSys AG.


This  communication contains  certain forward-looking  statements concerning the
MorphoSys  group of  companies. The  forward-looking statements contained herein
represent  the judgment of MorphoSys as of  the date of this release and involve
risks  and  uncertainties.  Should  actual  conditions differ from the Company's
assumptions,  actual  results  and  actions  may  differ from those anticipated.
MorphoSys  does not intend to update  any of these forward-looking statements as
far as the wording of the relevant press release is concerned.


For more information, please contact MorphoSys:

Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com 


[HUG#1377098]



 --- End of Message --- 

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:MIDCAP,HDAX,TecDAX,CDAX,TECH All Share,Prime All Share;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


    Press Release: http://hugin.info/130295/R/1377098/338202.pdf